BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
BIOMARIN PHARMACEUTICAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$54.67−0.01 (-0.02%)
Close on Oct 19, 2026
- Market cap
- $10.63B
- P/E (TTM)
- 143.9
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
77.7%+5.9 pts over 5 years
Operating margin
12.7%+15.0 pts over 5 years
Net margin
10.8%−35.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +12.9% | +15.4% | +11.6% | +13.7% | |
| Gross profit | +10.1% | +16.3% | +13.4% | +13.0% | |
| Operating income | -15.4% | +36.5% | – | – | |
| Net income | -18.3% | +35.1% | -16.4% | – | |
| EPS, diluted | -18.6% | +33.9% | -16.7% | – | |
| Free cash flow | +48.7% | +136.3% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -24.4% | 23.6% | 5.9% | |
| Return on assets | -16.3% | 16.2% | 4.8% | |
| Current ratio | 3.24 | 4.76 | 5.21 | |
| Interest coverage | -20.3× | -1.5× | 37.6× | |
| Inventory turnover | 0.7× | 0.8× | 0.6× | |
| Capex to revenue | 13.3% | 6.1% | 3.2% | |
| Diluted shares | 166M | 192M | 197M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Biomarin Pharmaceutical generated $2.04B from operations and spent $501.69M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$2.04B
Used
$501.69M
Capital expenditure$501.69M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin10.8%
×Asset turnover0.44×
×Equity multiplier1.24×
=Return on equity, FY20255.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 10.8% | 0.44× | 1.24× | 5.9% |
| FY2024 | 15.0% | 0.41× | 1.30× | 8.0% |
| FY2023 | 6.9% | 0.37× | 1.38× | 3.5% |
| FY2022 | 6.8% | 0.34× | 1.40× | 3.2% |
| FY2021 | -3.5% | 0.31× | 1.42× | -1.5% |
| FY2020 | 45.9% | 0.35× | 1.46× | 23.6% |
| FY2019 | -1.4% | 0.37× | 1.50× | -0.8% |
| FY2018 | -5.2% | 0.33× | 1.57× | -2.7% |
| FY2017 | -8.9% | 0.30× | 1.55× | -4.2% |
| FY2016 | -56.4% | 0.29× | 1.50× | -24.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$348.90M
- Cash generatingOperating cash flow above zero$827.99M
- Return on assets improvedROA up on the prior year6.2% → 5.0%
- Earnings backed by cashOperating cash flow above net income$827.99M vs $348.90M
- Less leverageLong-term debt to assets fell– → 7.9%
- Better liquidityCurrent ratio rose5.33 → 5.21
- No dilutionShare count did not rise197M → 197M
- Gross margin improvedGross margin up on the prior year79.67% → 77.73%
- More efficientAsset turnover rose0.42 → 0.46